john Posted July 21, 2003 Share Posted July 21, 2003 Trial Information Summary: A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 (Montanide) in Patients with Advanced Non-Small Cell Lung Cancer This lung cancer vaccine research study involves the injection of the NY-ESO-1b peptide along with 2 other agents to help stimulate the immune system. Peptides are small fragments of every protein. These peptides are normally found in the testis and the placenta. They have also been found on various types of cancer cells, such as non-small cell lung cancer. The purpose is to stimulate the immune system to react against the peptides that are found on cancer cells. Study Inclusion Criteria: Non-small cell lung cancer stages IIIB or IV who have either completed standard therapy (i.e. chemotherapy, radiation), declined standard therapy or found standard therapy was ineffective. 18 years old or older Tumor expression of the NY-ESO-1 antigen. HIV negative. Contact: Cathy Ferrara, RN, Clinical Trials Manager Weill Medical College of Cornell University 525 East 68th St, Box 110 New York, NY 10021 Telephone: 212-746-3328 Fax: 212-746-8223 Email: firstname.lastname@example.org Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.